BRCA1 inhibition of estrogen receptor signaling in transfected cells.

Mutations of the breast cancer susceptibility gene BRCA1 confer increased risk for breast, ovarian, and prostatic cancers, but it is not clear why the mutations are associated with these particular tumor types. In transient transfection assays, BRCA1 was found to inhibit signaling by the ligand-activated estrogen receptor (ER-alpha) through the estrogen-responsive enhancer element and to block the transcriptional activation function AF-2 of ER-alpha. These results raise the possibility that wild-type BRCA1 suppresses estrogen-dependent transcriptional pathways related to mammary epithelial cell proliferation and that loss of this ability contributes to tumorigenesis.

[1]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[2]  R. Evans,et al.  Nuclear Receptors in Sicily: All in the Famiglia , 1997, Cell.

[3]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[4]  A. Ferguson,et al.  Regulation of Estrogen Receptor α Function in Breast Cancer , 1997 .

[5]  H. Hanafusa,et al.  Evidence for a transcriptional activation function of BRCA1 C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. Verma,et al.  Transcriptional activation by BRCA1 , 1996, Nature.

[7]  N. Shao,et al.  Induction of apoptosis by the tumor suppressor protein BRCA1. , 1996, Oncogene.

[8]  B. Katzenellenbogen.  Estrogen receptors: bioactivities and interactions with cell signaling pathways. , 1996, Biology of reproduction.

[9]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[10]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[11]  W. Kaelin,et al.  E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Tjian,et al.  v-Src and EJ Ras alleviate repression of c-Jun by a cell-specific inhibitor , 1991, Nature.